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Two small  interstitial  dermatan  sulfate-containing 
proteoglycans, biglycan and decorin, are present in 
extracellular  matrices of skin,  tendon,  ligament,  and 
cartilage. We investigated the effects of biglycan and 
decorin  on the inhibition of a-thrombin  by  the  serine 
proteinase  inhibitor  heparin  cofactor 11. In solution, 
heparin  cofactor I1 inhibition of thrombin is acceler- 
ated by intact biglycan or decorin and by the  dermatan 
sulfate-containing  glycosaminoglycan (GAG) chains 
prepared from the  proteoglycans,  while  core  protein 
from  cartilage biglycan  had no effect.  L-Iduronic  acid- 
rich  skin decorin and GAG chains  had a greater accel- 
erating effect than  proteoglycan  and GAG chains  from 
cartilage  that  had  lower L-iduronic  acid  content. 
Treatment of skin  decorin  and GAG chains  with chon- 
droitinase ABC totally  eliminated  the  ability of these 
compounds  to accelerate  thrombin  inhibition by  hepa- 
rin cofactor I1 suggesting that  dermatan  sulfate  was 
responsible  for  this action. 
Both  biglycan and  decorin  bound  to  type V collagen 
in a saturable  and specific  manner.  Biglycan,  decorin, 
and core  protein  from  biglycan  competed  for  decorin 
binding to the  type V collagen,  while  only  the  intact 
proteoglycans competed for biglycan binding. When 
bound  to type V collagen,  both  biglycan and  decorin 
accelerated  the  heparin  cofactor  IIIthrombin  inhibition 
reaction as efficiently as the  proteoglycans  in solution. 
Our results  demonstrate  that  heparin  cofactor I1 in  the 
presence of biglycan or decorin bound to  type V colla- 
gen provides a “thromboresistant surface,” further 
suggesting a physiological  function for  these  proteins 
in  regulating  the  extravascular  activities of thrombin. 
Proteoglycans are  proteins  that have  one or more attached 
glycosaminoglycan (GAG)’ chains whose biological roles are 
determined by diverse carbohydrate and protein structural 
features. Proteoglycans function  in a  range of biological ac- 
tivities  that include  assembly of extracellular  matrix compo- 
nents, modulation of cell growth, hemostasis, and wound 
healing  through  interactions  with  various growth factors  and 
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other ligands. Some of the diverse actions of proteoglycans 
are mediated by the core protein and others by the GAG 
chains  (for a review, see Refs. 1 and 2). 
Dermatan  sulfate-containing proteoglycans (DSPGs) called 
biglycan and decorin are  present  in  the  extracellular  matrix 
of skin, tendon, ligament, meniscus, and articular cartilage 
(3-7) .  DSPGs  are  present  on collagen fibril  surfaces, and  they 
affect connective tissue  extracellular  matrix organization and 
function;  they  inhibit fibrillogenesis in vitro, and when bound 
to  fibronectin surfaces, they  can  alter cell adhesion  and mi- 
gration processes (3-9). Biglycan and decorin  have different 
core proteins,  and, whereas biglycan has two attached GAG 
chains, decorin has only one (6). The GAG chain composition 
is tissue-specific, with  the  chains of biglycan and decorin  from 
skin  containing -80% L-iduronic  acid (IdoA)  and  those from 
articular  cartilage  containing -40% IdoA (6). 
We are interested in the blood plasma serine proteinase 
inhibitors  heparin cofactor I1 (HC) (also called heparin cofac- 
tor,  dermatan  sulfate cofactor, antithrombin BM, and L,eu- 
serpin-2) and antithrombin (AT, historically termed anti- 
thrombin 111). HC and  AT  inhibit  thrombin  a  reaction that 
is  dramatically accelerated by the GAG heparin (for  a review, 
see Refs. 10  and 11). Heparan  sulfate-containing proteogly- 
cans are the physiologically relevant “heparin-like” GAG. 
They  are located on  the  luminal  and  abluminal surfaces of 
endothelial cells and  preferentially  interact with AT compared 
with HC (see Ref. 12 and work cited therein). In contrast, 
dermatan  sulfate  accelerates  thrombin  inhibition by HC  but 
not by AT (10, 12-14). DSPGs on cultured fibroblasts and 
vascular smooth muscle  cells have been  shown to accelerate 
thrombin inhibition by HC (15), and a soluble circulating 
DSPG in the plasma of pregnant women and their fetuses 
with  anticoagulant  activity  mediated by HC  has recently  been 
described (16). The  unique specificity of dermatan  sulfate for 
HC prompted us to investigate the interactions of purified 
biglycan and  decorin with HC  and  thrombin.  We  report here 
that  skin  and cartilage DSPGs in solution increase the  rate 
of thrombin  inhibition by HC  but  not by AT. Furthermore, 
biglycan and decorin bind  to  type V collagen, and when bound 
they accelerate thrombin inhibition by HC  as efficiently as 
the proteoglycans  in  solution. 
EXPERIMENTAL PROCEDURES 
Materials-HC, AT, and a-thrombin were purified as described 
previously (17, 18). Human type V collagen and BSA were from 
Sigma. Heparin was  provided  by Dr. G. van  Dedem of Diosynth BV, 
Oss, the Netherlands; porcine skin dermatan sulfate (Calbiochem) 
was treated  with  nitrous acid to degrade contaminating  heparin  and 
heparan  sulfate  (19).  Polybrene  and IODO-BEADS were purchased 
from  Aldrich and from Pierce Chemical Co., respectively. W-p-Tosyl- 
Gly-Pro-Arg-p-nitroanilide (Chromozym TH)  was from Boehringer 
Mannheim. 
Isolation of Biglycan and Decorin-Biglycan, decorin, IdoA-con- 
taining GAG chains,  and core proteins derived  from these proteogly- 
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cans were purified to homogeneity and  prepared  as described previ- 
ously (3, 6). Biglycan was  isolated from calf articular cartilage, and 
decorin was isolated from bovine fetal  skin. The isolation procedure 
involved extraction with 4 M guanidine hydrochloride, equilibrium 
density  gradient  centrifugation,  DEAE  chromatography,  and gel per- 
meation chromatography on Sepharose CL-4B in 4 M guanidine 
hydrochloride,  which separated  traces of aggrecan from biglycan and 
decorin. Decorin and biglycan were then  separated  from  each  other 
by octyl-Sepharose chromatography (6). The homogeneity of the 
individual  species,  decorin and biglycan, was then assessed by sodium 
dodecyl  sulfate-polyacrylamide gel electrophoresis. Furthermore, 
amino acid  sequencing and  Western  blotting  are routinely  performed, 
and these  analyses reveal  no contamination by aggrecan or serglycin 
was  detectable  in  either  the biglycan or  the decorin preparations. 
Radiolabeling and Chemical Modification of Proteins-cu-Thrombin 
was 1'51-labeled as described  previously (20). Cartilage biglycan and 
skin decorin were labeled  using  essentially the  same procedure. Chem- 
ical  modification of HC  and  thrombin with  pyridoxal 5"phosphate 
was performed as detailed  (21, 22). 
Thrombin Inhibition Assays-Thrombin (5 nM) and  HC (50 nM) 
in 20 mM HEPES, 150 mM NaCI, 0.1% (w/v) polyethylene glycol ( M ,  
= 8000) buffer at   pH 7.4 (HNP)  a t  room temperature were incubated 
with biglycan, decorin,  core protein,  or GAG chains  either  in  solution 
or bound to  type V collagen adsorbed  to 96-well microtiter  plates  as 
described below. At  various time  intervals, Chromozym TH was added 
with enough Polybrene to complex the GAG chains. The rate of 
Chromozym TH hydrolysis was monitored  using a V,,, kinetic  plate 
reader (Molecular  Devices) and was comparedwith  thrombin  controls 
(same reaction components minus HC). Assays were performed in 
quadruplicate,  and  the second order  rate  constant ( K , )  was determined 
according  to  the  equation kz = -In(E,/Eo)/[Io]t,  where t is  the  reaction 
time, E, and E, are remaining thrombin activity a t  time t and 
thrombin  control activity,  respectively, and [I0] is the  initial  inhibitor 
concentration (21). Skin decorin and isolated skin decorin GAG 
chains (0.5 ml  of 30 pg/ml) were treated for  2  h at  37 "C  with 1 p1 of 
chondroitinase ABC (10  units/ml;  Seikagaku America, Inc., St.  Pe- 
tersburg, FL). Following glycosidase treatment, the solutions were 
tested for residual activity  in  the  HC-thrombin  inhibition assay as 
detailed above.  A control  with glycosidase alone  had no  adverse  effect 
on  the  HC-thrombin  inhibition reaction (data  not  shown).  Molarity 
of GAG, DSPG,  and core protein  solutions was determined using the 
following M ,  values  (shown in  parentheses): cartilage biglycan 
(lOO,OOO), skin decorin  (67,000), cartilage biglycan core protein 
(37,280), GAG chains from cartilage biglycan or  skin decorin (30,000), 
commercial heparin (15,000), and commercial dermatan  sulfate 
(50,000). 
Binding of DSPGs to  Collagen-A stock (1 mg/ml)  type V collagen 
was  prepared using 0.5 M acetic acid  and  then  diluted to 10 wg/ml in 
20 mM HEPES, 150 mM NaCl buffer at   pH 7.4 (HBS).  The  diluted 
collagen  solution (100 p l )  was pipetted  into 96-well microtiter  plates 
and incubated  overnight on  a shaker  at 4 "C. The wells were rinsed 
once with 200 pl of HBS buffer and  then blocked for 1 h a t  4 "C with 
200 pI of HBS  containing 2% (w/v) BSA.  After the wells were rinsed 
three times with 200 p1 of HBS, 100 pl of proteoglycan or GAG 
solution were added and  incubated  overnight a t  4 "C. Control wells 
were  incubated  with  HBS alone. The wells were rinsed  three  times 
with  HBS  and allowed to dry a t  room temperature before assays were 
performed.  Experiments using Iz5I-DSPGs were performed  in  essen- 
tially  the  same  manner  except  Immulon 4  Remove-a-Well strips  and 
holders  (Dynatech  Laboratories, Inc.) were  used in  place of 96-well 
microtiter plates. The  amounts of hound  and free  proteoglycan were 
determined by placing individual wells with  DSPG  hound  and  samples 
of unbound  DSPG  remaining  in  supernatant, respectively, in a Pack- 
ard  Multi-Prias 1 y-radiation counter. The total number of counts 
recovered correlated well (290%) with  the  number of counts added. 
RESULTS 
Interaction of Soluble Dermatan  Sulfate Proteoglycans  with 
Heparin Cofactor I I  and Thrombin-Cartilage biglycan and 
GAG chains from cartilage biglycan accelerated  the  rate of 
the  HC-thrombin  inhibition  reaction  approximately 250-fold 
a t  a concentration of 5000 nM (Fig. 1, upperpanel). IdoA-rich 
skin decorin and GAG chains  from  skin decorin accelerated 
thrombin  inhibition by HC  about 2500-fold a t  5000 nM (Fig. 
I, upper panel). However, the core protein from cartilage 
biglycan did not accelerate thrombin inhibition by HC at 
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FIG. 1. Effect of biglycan, decorin, core protein, GAG 
chains, and glycosidase treatment of decorin and decorin GAG 
chains on the rate of thrombin inhibition by heparin cofactor 
11. Upper panel, 5 nM thrombin  and 50 nM HC were incubated with 
increasing  amounts of cartilage biglycan (O),  core protein from car- 
tilage biglycan (0), GAG chains from cartilage biglycan (m), skin 
decorin (A), or GAG chains from skin decorin (A). Lower panel, 
chondroitinase ABC was incubated with decorin and GAG chains 
from  skin decorin as described under  "Experimental Procedures." 5 
nM thrombin  and 50 nM HC were incubated  with decorin (a), 
glycosidase-treated decorin (W), GAG chains from skin decorin (A), 
and glycosidase-treated GAG chains from decorin (A), each at 30 nM. 
At timed  intervals,  portions were removed, and  thrombin activity was 
determined. 
concentrations  up  to 1000 nM (Fig. 1, upper panel). To elim- 
inate  the possibility that  another GAG other  than  dermatan 
sulfate was responsible for the accelerated inhibition, skin 
decorin and GAG chains from skin decorin were selectively 
degraded with chondroitinase ABC. Glycosidase treatment 
abolished (>95%) the  ability of these compounds to accelerate 
the  HC-thrombin  reaction (Fig. 1, lower panel).  Furthermore, 
chemical  modification of lysyl residues essential for heparin 
and  dermatan  sulfate  binding  in  either  HC or thrombin re- 
sulted in a dramatic decrease of the biglycan and decorin- 
accelerated inhibition rate (Table I). As expected, neither 
cartilage biglycan nor  skin decorin (at 10-25 pg/ml) enhanced 
the rate of the AT-thrombin inhibition reaction (rate con- 
stants  either in the absence or in the presence of DSPGs were 
3.3 x lo3 ~ - 1  s-l). 
These  results show that biglycan and decorin,  like  commer- 
cial  porcine skin  dermatan  sulfate,  accelerate  the  HC-throm- 
bin  inhibition  reaction.  Since  the  AT-thrombin  reaction was 
not  stimulated by these  DSPGs  (eliminating a heparan  sulfate 
or heparin  contaminant from mediating  the observed activity) 
and since the  hexosamine-uronic acid linkages of dermatan 
sulfate  in  skin decorin and  isolated GAG chains  are  sensitive 
to chondroitinase ABC, our results indicate that dermatan 
sulfate is responsible  for the accelerated inhibition of throm- 
bin by HC. Our results also suggest that a decrease in the 
biglycan and  decorin-accelerated  inhibition following modifi- 
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TABLE I 
Effrct of lysine-modified  thrombin and  heparin cofactor I I  on DSPG acceleration of the  heparin cofactor II-thrombin  reaction 
Phosphopyridoxylated  thrombin (PLP-T) and  HC  species  (PLP-HC) were prepared  and  compared  with  reduced  control  thrombin  (rc-T) 
and HC species (rc-HC) as described  (21,  22).  Reaction  conditions  were  50 nM HC, 5 nM thrombin, 10 pg/ml  DSPG,  dermatan  sulfate, or 
(;A(; chains  from  skin  decorin  in H N P  for 1 or 10  min a t  room  temperature.  Thrombin  activity  remaining  and  calculation f kl values were 
determined as detailed  under  "Experimental  Procedures." 
Inhibition rate constant (kf X 10') 
rc-HC/rc-T PLP-HC/rc-T rc-HC/PLP-T PLP-HC/PLP-T 
Reaction  addition 
M" S" 
Dermatan  sulfate" 72 43 6.7 17 
Skin  decorin" 118 28 NDb 3.3 
Skin  decorin GAG chains" 133 25 ND 6.7 
Cartilage decorin' 18 10 0.6  0.6 
Cartilage hialvcan' 18 8.3 0.3 1.3 
" In HNP for 1 min. 
* ND, no detectable  thrombin  inhibition (k? < 0.3 X loT M" s-'). 
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FIG. 2. Activation of heparin cofactor I1 in human plasma 
by biglycan, decorin, and GAG chains. Citrated  human  plasma 
(diluted 1 5 0  in HNP) was  incuhated  with "'1-thrombin (5 nM) and 
either biglycan,  decorin, GAG chains  from  skin  decorin,  commercial 
dermatan  sulfate, or heparin  in  solution  for 5 min a t  room  tempera- 
ture  and  then analyzed hy sodium  dodecyl  sulfate-polyacrylamide gel 
electrophoresis  and  autoradiography as described  (20).  Lane I ,  control 
with  purified  HC and  10  pg/ml  (200 nM) commercial  dermatan 
sulfate: lnnrs 2-6, plasma  with 10 pg/ml commercial  dermatan  sulfate 
(900 nM), cartilage higlycan (100 nM), cartilage decorin (150 nM), 
skin decorin (150 nM), and GAG chains  from  skin  decorin  (333 nM), 
respectively; lane 7, plasma with 1 pg/ml heparin (67 nM); lane 8, 
control  with  purified A T  and 1 pg/ml  heparin (67 nM); lane 9, plasma 
with  ""I-thrombin  only  added;  lane IO. ""I-thrombin  only. 
cation of lysyl residues in either  HC or thrombin is consistent 
with a ternary complex model, which requires binding of both 
proteinase  and  inhibitor  to  the GAG chains of biglycan and 
decorin in order for accelerated inhibition  to occur (21,22). 
Actiuation of Heparin Cofactor II in Human Plasma by 
Dermatan  Sulfate Proteoglycans-We compared  the  ability of 
soluble biglycan, decorin, and GAG chains  to  preferentially 
"activate" HC over AT by measuring thrombin. HC and 
thrombin  .AT complex formation in plasma  using exogenous 
'""I-labeled thrombin.  The  DSPGs  and GAG chains  activated 
plasma  HC, in approximately decreasing order of effective- 
ness, as follows: skin decorin = GAG chains from skin decorin 
=: commercial dermatan  sulfate > cartilage biglycan =: carti- 
lage decorin (Fig. 2). The  amount of radiolabeled thrombin 
incorporated  into a complex with plasma A T  did not increase 
in  the presence of any of the  DSPGs (Fig. 2). These  results 
demonstrate  that soluble biglycan, decorin, and GAG chains 
from skin decorin  preferentially promote  thrombin. HC over 
thrombin.  AT complex formation in an ex  uiuo plasma  system. 
Binding of Dermatan  Sulfate Proteoglycans to Type V Col- 
lagen-There is substantial evidence that DSPGs found in 
uiuo in  extracellular matrix  are noncovalently bound  to col- 
lagens (23). We prepared a surface composed of biglycan and 
decorin bound to type V collagen to simulate a relatively 
physiological extravascular environment. Fig. 3 shows the 
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FIG. 3. Binding of ""I-cartilage biglycan and '*'I-skin de- 
corin to type V collagen. Upper panel,  increasing  concentrations 
of Y - s k i n  decorin were incubated on type V collagen (A) or BSA 
(0). Lower panel,  increasing  concentrations of "'I-cartilage biglycan 
were  incubated  on  type V collagen (0) or BSA (0). 
binding of increasing amounts of '""Iskin decorin (upper 
panel) and '2sII-cartilage biglycan (lower punel) to type V 
collagen or BSA-coated wells. Both proteoglycans  bound sig- 
nificantly to the type V collagen, and binding appeared to 
saturate at approximately 2 pmol/well for '2sI-cartilage bi- 
glycan and 1.4 pmol/well for '"1-skin decorin.  Binding of both 
proteoglycans to the BSA-coated wells was significantly lower, 
appearing  to  saturate a t  -0.3-0.4 pmol/well (Fig. 3). 
Cartilage biglycan, skin decorin, and core protein from 
cartilage biglycan competed for ",'I-skin decorin binding to 
type V collagen while GAG chains from skin decorin did not 
(Fig. 4, upper panel).  Interestingly, only intact cartilage bi- 
glycan and  skin decorin  competed for '2sII-cartilage biglycan 
Heparin Cofactor 11 and  Dermatan  Sulfate  Pro oglycans 3923 
0.04 . , . , . , , , . , . , . I 
0 IO 20 30 40 50 60 70 
Added Competitor  (pmol/well) 
0.04 . , . , . , . , . , , , . I 
0 10 20 30 40 50 60 70 
Added Competitor  (pmol/well) 
FIG. 4. Competition for binding of '261-cartilage biglycan 
and '''I-skin decorin to type V collagen. Upper  panel, 3 pmol of 
""-skin decorin was incubated on type V collagen with increasing 
amounts of unlabeled skin decorin (A), GAG chains from skin decorin 
(A), cartilage biglycan (01, or core protein from cartilage biglycan 
(D). Lower panel, 3 pmol of 12sI-cartilage biglycan was incubated  on 
type V collagen with increasing amounts of unlabeled cartilage bi- 
glycan (O), core protein from cartilage biglycan (H), skin decorin (A), 
GAG chains from cartilage biglycan (O), or an equimolar  mixture of 
core protein from cartilage biglycan and GAG chains from cartilage 
biglycan (0). 
binding. Core protein from cartilage biglycan, GAG chains 
from cartilage biglycan, as well as  an equimolar mixture of 
the two showed little or no  competition (Fig. 4, lower panel). 
Unlabeled skin decorin (Fig. 4, upper panel) and cartilage 
biglycan (Fig. 4, lower panel) reduced binding of the  corre- 
sponding labeled  proteoglycan to  the level of binding of the 
'"1-proteoglycan to BSA (Fig.  3). These  results suggest that 
both cartilage biglycan and skin decorin bind to type V 
collagen in a saturable  and specific manner. 
Interaction of Bound  Dermatan  Sulfate Proteoglycans with 
Heparin Cofactor I I  and Thrombin-To test  the  activity of 
these  surface-bound  DSPGs,  thrombin  inhibition by HC was 
measured  in  the  presence of biglycan and decorin bound to 
type V collagen. Either '251-cartilage biglycan or T - s k i n  
decorin (both at  7.5 pmol/well) was added to wells coated 
with  type V collagen, and averages of  0.95 pmol/well biglycan 
and 0.75 pmol/well decorin bound to the type V collagen 
surface.  Inhibition  rate  constants of 1.25 x lo3 and 7.0 x lo3 
M" s" were measured  for thrombin  inhibition by HC  in  the 
presence of the  bound '251-cartilage biglycan and  bound lZ5I- 
skin decorin, respectively. As a further  confirmation of the 
ability of bound  DSPGs  to  accelerate  HC  inhibition of throm- 
bin, solution assays with identical  amounts of unlabeled pro- 
teoglycan gave rate  constants of 1.1 X lo3 and 6.8 X lo3 M" 
s-' for  cartilage biglycan and  skin  decorin, respectively. Con- 
trol  experiments showed the  solution  activity of radiolabeled 
and unlabeled proteoglycans to be identical. A normal rate 
constant for HC inhibition of thrombin in the absence of 
GAG (0.62 X lo3 M" s-') was determined for the collagen 
surface alone.  The surface prepared by incubating  either GAG 
chains from skin decorin, commercial dermatan sulfate, or 
HBS  alone  with  type V collagen did  not accelerate thrombin 
inhibition by HC  (data  not included). These  results  demon- 
strate  that biglycan and decorin bound  to  type V collagen are 
able  to  accelerate  HC  inhibition of thrombin  as efficiently as 
the proteoglycans  in solution. 
DISCUSSION 
Proteoglycans are now known to be active, not passive, 
participants in many biological events (1, 2). Their unique 
structures supply a versatile scaffolding for processes me- 
diated by many  eukaryotic cell surfaces and by most  pericel- 
lular  and  extracellular matrices. This investigation was un- 
dertaken  to  determine if biglycan and decorin  purified  from 
skin  and  articular cartilage could accelerate thrombin  inhibi- 
tion  in  the  presence of the  plasma  serine  proteinase  inhibitor, 
HC. A physiological role for HC is not firmly established; 
however, we and others have suggested that physiological 
activation of HC is mediated  through  dermatan  sulfate,  prob- 
ably in  the form of a DSPG  (10,11, 13-15, 24). 
Biglycan,  decorin, and  their purified GAG chains, in  solu- 
tion phase assays, accelerate thrombin inhibition by HC, 
while the  core  protein from biglycan does not. The activity of 
bovine fetal  skin  decorin  and  its GAG chains  at 5000 nM is 
-40% of the same concentration of commercial dermatan 
sulfate  (10). A possible explanation is that  the decorin GAG 
chains (Mr = 30,000) are  smaller  than  the commercial der- 
matan  sulfate (Mr = 50,000) and would therefore have fewer 
binding  sites available for HC  and  thrombin. Alternatively, 
these  DSPGs may contain less of the  dermatan  sulfate hexa- 
saccharide that binds with high affinity to HC (24). Skin 
decorin and GAG chains from skin decorin are more effective 
than biglycan and biglycan GAG chains from articular  carti- 
lage at  accelerating the HC-thrombin reaction. Therefore, 
this suggests that in  uiuo DSPGs  containing a  larger ratio of 
IdoA to  D-glucuronic acid (i.e. more dermatan  sulfate  than 
chondroitin sulfate disaccharides) would be more proficient 
in  accelerating  HC  inhibition of thrombin. 
Evidence for proteoglycan-collagen interactions in many 
connective tissues  is firmly established  (23).  DSPGs  bind  to 
types I and VI collagen and  other ligands both  through GAG 
chains  and  through core protein  interactions  (9, 23, 25, 26). 
Type V collagen is  found in a wide variety of tissues,  both 
adjacent  to  basement  membranes  and in  fibrous stroma,  and 
has been  shown to be adjacent  to  peripheral capillaries and 
at   the surface of blood vessels denuded of their  endothelial 
lining (27). Tissue distribution similarities for DSPGs and 
type V collagen indicate  that  they  should  be a suitable model 
of an  extravascular surface.  Cartilage  biglycan, skin decorin, 
and core protein from cartilage biglycan compete for skin 
decorin binding to type V collagen, while the GAG chains 
from skin decorin do not.  This suggests that  the  binding of 
skin  decorin  to  type V collagen is mediated through decorin 
core  protein.  Interestingly, while intact cartilage biglycan and 
skin decorin prevent  the  binding of cartilage biglycan to  type 
V collagen, core protein from cartilage biglycan and GAG 
chains from cartilage biglycan do  not compete. This implies 
that GAG chains may be required  for biglycan binding  to  type 
V collagen. However, core protein from cartilage biglycan 
does compete for binding of skin decorin to  type V collagen 
as effectively as  intact biglycan. It may be that biglycan and 
decorin  bind  to  different sites on  type V collagen, and, while 
3924 Heparin  Cofactor 11 and  Dermatan Sulfate  Proteoglycans 
only core protein is necessary for decorin binding, intact 
proteoglycan is necessary for biglycan binding. Further ex- 
periments  are needed to  delineate  the  details of biglycan and 
decorin  interactions with type V collagen. 
An exciting finding  is  that biglycan and decorin bound  to 
type V collagen are capable of accelerating  the  HC-thrombin 
reaction  as efficiently as  the proteoglycans in  solution.  The 
activity of the  bound DSPGs is  not due to  their release into 
solution  (by  thrombin proteolysis or  other  mechanisms)  since 
the  quantitation of amount  bound was performed after  the 
inhibition assays, and  all wells had  similar  amounts of DSPG 
bound, regardless of the  time  incubated (15-60 min)  or 
whether  the well contained  inhibitor  (HC-thrombin  reaction) 
or  not  (thrombin  controls).  In  the  assays,  bound  decorin  had 
a concentration of 75 nM, and  the increase of inhibition  rate 
was  modest (-11-fold). Local in vivo concentrations of DSPGs 
may be significantly  higher  because of a greater  extracellular 
matrix  (and cell surface) to  extracellular fluid volume ratio 
(15).  It  is also not known how great  an increase in  inhibition 
rate is necessary  for  regulation of thrombin activity. There- 
fore, following endothelial injury, plasma  HC may be specifi- 
cally “anchored  to  dermatan  sulfate  chains  in  extracellular 
matrix  and regulate the  multiple biological activities of throm- 
bin.  Another possible function of HC anchored  in  the  extra- 
cellular matrix could be to localize HC for proteolysis by 
neutrophil  elastase  and  cathepsin G with release of a leuko- 
cyte  chemoattractant  peptide (28,29). 
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